Cash from Financing (Quarterly) Chart

Historical Cash from Financing (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
September 30, 2026 5.69M
June 30, 2026 -0.282M
March 31, 2026 18.94M
December 31, 2025 -0.119M
September 30, 2025 4.482M
June 30, 2025 -2.135M
March 31, 2025 7.537M
December 31, 2024 8.831M
September 30, 2024 -1.524M
June 30, 2024 -1.464M
March 31, 2024 -2.406M
December 31, 2023 -2.118M
September 30, 2023 12.56M
June 30, 2023 -0.852M
March 31, 2023 -2.006M
December 31, 2022 -1.388M
September 30, 2022 4.662M
June 30, 2022 -0.759M
March 31, 2022 -1.648M
December 31, 2021 -1.312M
September 30, 2021 -0.956M
June 30, 2021 -0.575M
March 31, 2021 -1.329M
December 31, 2020 165.24M
September 30, 2020 5.82M
Date Value
June 30, 2020 16.48M
March 31, 2020 1.277M
December 31, 2019 -1.061M
September 30, 2019 0.567M
June 30, 2019 -5.369M
March 31, 2019 29.13M
December 31, 2018 -1.639M
September 30, 2018 -1.36M
June 30, 2018 -1.147M
March 31, 2018 -1.815M
December 31, 2017 -1.473M
September 30, 2017 34.71M
June 30, 2017 -0.505M
March 31, 2017 31.51M
December 31, 2016 0.692M
September 30, 2016 -0.615M
June 30, 2016 -0.3215M
March 31, 2016 -1.122M
December 31, 2015 -0.366M
September 30, 2015 -1.108M
June 30, 2015 -0.922M
March 31, 2015 64.06M
December 31, 2014 -0.7474M
September 30, 2014 -0.8138M
June 30, 2014 0.0764M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Lineage Cell Therapeutics, Inc. -0.023M
Agenus, Inc. 87.56M
Amgen, Inc. -4.391B
Anika Therapeutics, Inc. -0.027M
BioCryst Pharmaceuticals, Inc. -11.78M